Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q3 2017 · 10-Q
Revenue$11.95M$11.95M+2,828.9% vs Q3 2016 Net Income-$13.26M-$13.26MN/M vs Q3 2016 EPS Diluted-$0.45-$0.45N/M vs Q3 2016 Operating Income-$13,430,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$12,907,000N/M Margins · derivedOperating margin-112.4%+6368.5 pt vs Q3 2016
Net margin-111.0%+6370.4 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 8, 2017 · 39 d after period end